Abstract Details

Title Neurological Manifestations of Patients Hospitalized with COVID-19 Diagnosis at OLSU-S

Topic General Neurology

Presentation(s) General Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 013

Objective To determine the spectrum of neurological manifestations among COVID-19 patients admitted to Ochsner-Louisiana State University Health Sciences Center, Shreveport (OLSU-S) after SARS-CoV-2 positive results.

Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is associated with increased incidence and prevalence of well-defined neurological manifestations. Based on clinical reports there is vast spectrum of neurological disorders associated with COVID-19 patients including metabolic encephalopathy, cerebrovascular disease, seizure disorder, and myelopathies.

Design/Methods We conducted a retrospective, observational study of hospitalized adult patients (age > 18 years) admitted to OLSU-S with laboratory confirmed SARS-COV-2. All clinical data was reviewed including epidemiology, clinical features, laboratory data, neuroradiological findings, hospital management and course from 150 patients hospitalized for COVID-19 management at OLSU-S.

Results We screened 150 patients admitted to OLSU-S with COVID-19 for the development of neurological diagnosis during their hospital course. 19 (12.66%) patients presented with new neurological signs and symptoms and were subsequently diagnosed with a neurological disorder within the active COVID-19 infection period. The most common new neurological manifestation seen with COVID-19 was acute cerebrovascular accidents (CVA) (6%) followed by encephalopathy (4.66%), seizures (4%) and Guillain-Barre like syndrome (1.33%). The mean age of patients with neurological diagnosis was 60.74 ± 14.58 (standard deviation) (age range 25-76). The common neuroradiological diagnosis on COVID-19 patients with acute CVA includes middle cerebral artery infarction, venous infarction and hemorrhagic CVA. The most common EEG findings was diffuse background slowing consistent with moderate encephalopathy. 26% of the patients with new neurological diagnosis during acute COVID-19 had rapid clinical deterioration resulting in death.

Conclusions Our observations confirm the increased incidence of neurological manifestations seen in COVID-19 patients, with the elderly population being more susceptible. The subsequent development of a neurological disorder during COVID-19 was found to be associated with worse clinical outcomes and an overall poor prognosis.

Authors/Disclosures
Junaid Ansari, MD (LSU Health Shreveport) PRESENTER	Dr. Ansari has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Rosario Maria S. Riel-Romero, MD, FAAN (Louisiana State University School of Medicine in Shreveport)	Dr. Riel-Romero has stock in Biointech. Dr. Riel-Romero has stock in Intuitive Surgical. Dr. Riel-Romero has stock in CRISPR. Dr. Riel-Romero has received personal compensation in the range of $100,000-$499,999 for serving as a Professor with LSU. An immediate family member of Dr. Riel-Romero has received personal compensation in the range of $100,000-$499,999 for serving as a Surgeon with VA.
	No disclosure on file
Roger E. Kelley, Jr., MD, FAAN (LSU Health Sciences Center)	Dr. Kelley has nothing to disclose.

��ɫ��

��ɫ��